Sacituzumab Govitecan Provides More Treatment Options in HER2– Breast Cancer
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
The FDA’s previous approval of sacituzumab govitecan-hziy (Trodelvy) has opened up new treatment options outside of standard chemotherapy for patients with hormone receptor (HR)–positive or HER2-negative or -low metastatic breast cancer who are endocrine therapy refractory, according to Sara M. Tolaney, MD, MPH.
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, about how findings from the phase 3 TROPiCS-02 study’s (NCT03901339) final overall survival analysis further support the benefit of sacituzumab govitecan in this population following the FDA’s approval of the agent in February 2023.1,2
Data from the analysis highlighted that sacituzumab govitecan improved overall survival in the HER2 IHC0 (Hazard ratio [HR], 0.85; 95% CI, 0.63-1.14) and HER2-low populations vs single agent chemotherapy (HR, 0.75; 95% CI, 0.57-0.97).
Transcript:
It's really exciting to have more treatment options for patients with pretreated metastatic [HR]-positive disease. The data from TROPiCS-02 certainly reinforces that sacituzumab govitecan does have benefit for this population, not just in terms of progression-free survival, but also in terms of a clinically meaningful and significant improvement in survival. It has opened up treatment options.
Many patients who are HER2-low will start off with a line of standard chemotherapy, go on to get [trastuzumab deruxtecan; Enhertu], and then subsequently go on to get sacituzumab. For those patients who are not HER2-low, [who] have a HER2 IHC of 0, and [estrogen receptor]–positive [disease], then we're often turning to sacituzumab even earlier. [Patients] will often get a line of chemotherapy and then go to sacituzumab. [The approval of sacituzumab] is allowing for more choices outside of just standard chemotherapy once people become endocrine refractory, which is great for patients.
References
- U.S FDA approves Trodelvy in pre-treated HR+/HER2- metastatic breast cancer. News release. Gilead. February 3, 2023. Accessed June 5, 2023. https://bwnews.pr/3Y0bftX
- Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003
